

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

OPM-2

RRID:CVCL_1625

Type: Cell Line

Proper Citation

RRID:CVCL_1625

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1625

Proper Citation: RRID:CVCL_1625

Description: Cell line OPM-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:3926660](#), [PMID:8943038](#), [PMID:10087940](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:20164919](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces Ig lambda., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OPM-2

Synonyms: OPM2

Cross References: BTO:BTO_0005919, CLO:CLO_0008269, EFO:EFO_0006716, CLDB:cl3774, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-

MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, BioGRID_ORCS_Cell_line:977, BioSample:SAMN03473240, BioSample:SAMN10988562, cancercellines:CVCL_1625, Cell_Model_Passport:SIDM00457, CGH-DB:36-1, CGH-DB:9158-4, ChEMBL-Cells:ChEMBL3308883, ChEMBL-Targets:ChEMBL2366353, Cosmic:720767, Cosmic:735529, Cosmic:759901, Cosmic:759907, Cosmic:760390, Cosmic:760403, Cosmic:909249, Cosmic:1889515, Cosmic:2081432, Cosmic:2302417, Cosmic:2367300, Cosmic:2391792, Cosmic:2809760, Cosmic-CLP:909249, DepMap:ACH-000024, DSMZ:ACC-50, DSMZCellDive:ACC-50, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909249, GEO:GSM143336, GEO:GSM290303, GEO:GSM562818, GEO:GSM887478, GEO:GSM888559, GEO:GSM1374799, GEO:GSM1670307, IARC_TP53:21603, IARC_TP53:28518, LiGeA:CCLE_834, LINCS_LDP:LCL-2048, PharmacDB:OPM2_1202_2019, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_1625, PubChem_Cell_line:CVCL_1625, Wikidata:Q54936482

ID: CVCL_1625

Record Creation Time: 20220427T221359+0000

Record Last Update: 20260920T005343+0000

Ratings and Alerts

No rating or validation information has been found for OPM-2.

No alerts have been found for OPM-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. Molecular cancer therapeutics, 25(6), 1016.

- Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. *The Journal of biological chemistry*, 302(4), 111302.
- Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. *British journal of pharmacology*, 183(12), 3355.
- Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.
- Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. *Molecular oncology*.
- Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.
- Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. *Cell reports. Medicine*, 6(10), 102400.
- Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. *bioRxiv : the preprint server for biology*.
- Oudaert I, et al. (2025) PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. *Molecular oncology*.
- Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. *Molecular oncology*, 19(6), 1687.
- Ticona-Pérez FV, et al. (2024) Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. *Cancer cell international*, 24(1), 275.
- Costacurta M, et al. (2024) Mapping the IMiD-dependent cereblon interactome using BioID-proximity labelling. *The FEBS journal*.
- Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. *Research square*.
- Pu J, et al. (2024) Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. *Clinical & translational immunology*, 13(3), e1500.
- Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.
- Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Beltrán-Visiedo M, et al. (2023) Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. *Molecular oncology*, 17(12), 2507.